Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data

Background and purpose: poly-ADP ribose polymerase (PARP) inhibitors show impressive efficacy in a range of tumors. However, concerns about rare and fatal adverse events, including myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) have arisen. The aim of this study was to excavate...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Quanfeng, Ma, Pan, Fu, Peishu, Wang, Jiayu, Wang, Kejing, Chen, Lin, Yang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240214/
https://www.ncbi.nlm.nih.gov/pubmed/35784751
http://dx.doi.org/10.3389/fphar.2022.912256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240214/
https://www.ncbi.nlm.nih.gov/pubmed/35784751
http://dx.doi.org/10.3389/fphar.2022.912256

Ejemplares similares